MM-691: Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM) — Meletios A Dimopoulos (2025) | RDL Network
Meletios A Dimopoulos, Peter W. Voorhees, F. Hellem Schjesvold, Yaël C. Cohen, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksac, Keith Stockerl‐Goldstein, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Annelore Cortoos, Eva G. Katz, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar
Meletios A Dimopoulos, Peter M. Voorhees, Hartmut Goldschmidt, Ross Baker, Yingqi Shi, Els Rousseau, Robyn Monet Dennis, Robin Carson, S. Vincent Rajkumar
Meletios A Dimopoulos, Peter M. Voorhees, Fredrik Schjesvold, Yaël C. Cohen, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksac, Keith Stockerl‐Goldstein, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Sara Galimberti, Katarina Uttervall,
Sagar Lonial, Hang Quach, Meletios A Dimopoulos, Paula Rodríguez‐Otero, Jesús G. Berdeja, Paul G. Richardson, Margee Kyada, Shuyu Chu, Min Chen, Patricia C. Abad, Juliane Morando, Niels W.C.J. van de Donk
Discussion(0)
No comments yet. Be the first to comment.